通化金马新药进入最后审评环节，近期业绩已披露 每日视讯

Core Viewpoint - Tonghua Golden Horse has made significant progress in the development of its new chemical drug, Amber Dihydroaminoacridine Tablets, which has completed comprehensive review work and is now in the final review stage, marking it as a noteworthy event in the near term [2] Financial Performance - For the third quarter of 2025, the company reported revenue of 892 million yuan and a net profit attributable to shareholders of 24.96 million yuan [2]